Northwell Health Launches Psychedelics Research Center to Tackle Severe Mental Health Disorders
Event summary
- Northwell Health opened the Center for Psychedelics Research and Treatment (CPRT) at Zucker Hillside Hospital on January 27, 2026.
- The CPRT will focus on researching psychedelics like psilocybin, MDMA, and ketamine for treating severe mental health and substance use disorders.
- Initial studies include psilocybin for social anxiety, MDMA for schizophrenia, and naturalistic psychedelics use assessment.
- The center aims to complete initial research and launch clinical treatment programs within five years.
The big picture
Northwell Health's investment in psychedelics research aligns with the growing industry trend towards exploring alternative treatments for mental health disorders. The CPRT's focus on severe conditions like schizophrenia and opioid use disorders positions Northwell at the forefront of this emerging field, potentially influencing future healthcare policies and treatment standards. The center's long-term goal of establishing regional and national conferences underscores its ambition to become a leader in psychedelic science.
What we're watching
- Regulatory Approvals
- The pace at which regulatory approvals for psychedelic therapies will impact the CPRT's ability to offer clinical care.
- Research Outcomes
- Whether the initial studies on psilocybin, MDMA, and naturalistic use will yield significant findings to support broader applications.
- Expansion Plans
- How quickly Northwell can expand the CPRT's facilities and satellite programs across its 28-hospital footprint.
Our editorial coverage:
Related topics